CIK 0002012593
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 880724208
- Phone
- +1 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- Open-market buys, last 90 days
- $22,023,904
- in 7 filings
- Open-market sales, last 90 days
- $4,470,180
- in 7 filings, $4.5M under 10b5-1 plans
Net +$17,553,724. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,147 | $28.84 | $62K | 33,831 |
| 2025-12-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,421 | $30.04 | $73K | 31,410 |
| 2025-12-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −515 | $31.04 | $16K | 30,895 |
| 2025-12-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −7,704 | $29.95 | $231K | 393,438 |
| 2025-12-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −796 | $30.68 | $24K | 392,642 |
| 2025-11-26 | Gault Cheryl Chief Operating Officer | Sale 10b5-1 | −5,000 | $30.10 | $150K | 171,928 |
| 2025-11-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,777 | $24.92 | $69K | 576,802 |
| 2025-11-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −3,056 | $25.43 | $78K | 573,746 |
| 2025-11-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,242 | $24.91 | $56K | 38,819 |
| 2025-11-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,841 | $25.44 | $72K | 35,978 |
| 2025-11-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −3,156 | $24.84 | $78K | 406,486 |
| 2025-11-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −5,344 | $25.39 | $136K | 401,142 |
| 2025-10-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −7,418 | $25.73 | $191K | 410,724 |
| 2025-10-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −1,082 | $26.16 | $28K | 409,642 |
| 2025-10-15 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −4,647 | $25.72 | $120K | 580,765 |
| 2025-10-15 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −1,186 | $26.14 | $31K | 579,579 |
| 2025-10-15 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −4,328 | $25.75 | $111K | 41,816 |
| 2025-10-15 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −755 | $26.17 | $20K | 41,061 |
| 2025-09-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −39,435 | $26.30 | $1.0M | 586,812 |
| 2025-09-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −1,400 | $26.87 | $38K | 585,412 |
Page 4 of 5 · 92 trades